• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

芬戈莫德(FTY720)在淋巴组织中的蓄积有助于延长疗效。

Accumulation of fingolimod (FTY720) in lymphoid tissues contributes to prolonged efficacy.

作者信息

Sensken Sven-Christian, Bode Constantin, Gräler Markus H

机构信息

Institute for Immunology, Hannover Medical School, 30625 Hanover, Germany.

出版信息

J Pharmacol Exp Ther. 2009 Mar;328(3):963-9. doi: 10.1124/jpet.108.148163. Epub 2008 Dec 12.

DOI:10.1124/jpet.108.148163
PMID:19074680
Abstract

The immunomodulator fingolimod (FTY720) induces lymphopenia by inhibiting lymphocyte egress from thymus and secondary lymphoid organs (SLOs). It is phosphorylated mainly by sphingosine kinase (SK) 2 in vivo. FTY720-phosphate (FTY-P) activated and rapidly internalized S1P(1), which is the major sphingosine 1-phosphate (S1P) receptor for mediating lymphocyte egress. Although FTY-P is thought to be the active metabolite for triggering the onset of lymphopenia, nonphosphorylated FTY720 was much more potent in inhibiting cellular calcium flux and splenocyte chemotaxis via S1P(1) than FTY-P after preincubation. Determination of both compounds by liquid chromatography coupled to mass spectrometry revealed efficient uptake and accumulation of FTY720 but not FTY-P by splenocytes. Coculture experiments of B and T cells with and without FTY720 pretreatment led to rapid cellular transfer and phosphorylation by mouse lymphocytes. The presence of FTY720 in lymphoid tissues of FTY720-treated SK2-deficient mice without onset of lymphopenia excluded a potential role of the nonphosphorylated compound for lymphocyte egress. Local concentrations of both phosphorylated and nonphosphorylated FTY720 were much higher in lymphoid tissues than in blood. Therefore, we conclude that cellular accumulation of FTY720 generates a reservoir in thymus and SLOs, leading to sustained FTY-P production and activation of S1P(1) within tissues.

摘要

免疫调节剂芬戈莫德(FTY720)通过抑制淋巴细胞从胸腺和二级淋巴器官(SLOs)逸出而诱导淋巴细胞减少。它在体内主要由鞘氨醇激酶(SK)2磷酸化。磷酸化芬戈莫德(FTY-P)激活并迅速内化S1P(1),S1P(1)是介导淋巴细胞逸出的主要1-磷酸鞘氨醇(S1P)受体。尽管FTY-P被认为是引发淋巴细胞减少症发作的活性代谢物,但预孵育后,非磷酸化的FTY720在通过S1P(1)抑制细胞钙通量和脾细胞趋化性方面比FTY-P更有效。通过液相色谱-质谱联用测定这两种化合物,结果显示脾细胞对FTY720有高效摄取和积累,而对FTY-P则没有。对B细胞和T细胞进行有无FTY720预处理的共培养实验,结果显示小鼠淋巴细胞能使细胞快速转移并磷酸化。在未经淋巴细胞减少症发作的经FTY720处理的SK2缺陷小鼠的淋巴组织中存在FTY720,这排除了非磷酸化化合物在淋巴细胞逸出中的潜在作用。磷酸化和非磷酸化的FTY720在淋巴组织中的局部浓度均远高于血液中的浓度。因此,我们得出结论,FTY720在细胞内的积累在胸腺和SLOs中形成了一个储备库,导致组织内持续产生FTY-P并激活S1P(1)。

相似文献

1
Accumulation of fingolimod (FTY720) in lymphoid tissues contributes to prolonged efficacy.芬戈莫德(FTY720)在淋巴组织中的蓄积有助于延长疗效。
J Pharmacol Exp Ther. 2009 Mar;328(3):963-9. doi: 10.1124/jpet.108.148163. Epub 2008 Dec 12.
2
Production and release of sphingosine 1-phosphate and the phosphorylated form of the immunomodulator FTY720.鞘氨醇-1-磷酸及免疫调节剂FTY720磷酸化形式的产生与释放。
Biochim Biophys Acta. 2008 Sep;1781(9):496-502. doi: 10.1016/j.bbalip.2008.05.003. Epub 2008 Jun 13.
3
Phosphorylation of the immunomodulator FTY720 inhibits programmed cell death of fibroblasts via the S1P3 receptor subtype and Bcl-2 activation.免疫调节剂FTY720的磷酸化通过S1P3受体亚型和Bcl-2激活抑制成纤维细胞的程序性细胞死亡。
Cell Physiol Biochem. 2010;26(1):67-78. doi: 10.1159/000315107. Epub 2010 May 18.
4
The sphingosine 1-phosphate transporter, SPNS2, functions as a transporter of the phosphorylated form of the immunomodulating agent FTY720.鞘氨醇-1-磷酸转运蛋白 SPNS2 是免疫调节剂 FTY720 磷酸化形式的转运蛋白。
J Biol Chem. 2011 Jan 21;286(3):1758-66. doi: 10.1074/jbc.M110.171116. Epub 2010 Nov 17.
5
Role of sphingosine 1-phosphate receptor type 1 in lymphocyte egress from secondary lymphoid tissues and thymus.1-磷酸鞘氨醇受体1在淋巴细胞从次级淋巴组织和胸腺中逸出过程中的作用。
Cell Mol Immunol. 2006 Feb;3(1):11-9.
6
FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors.新型免疫调节剂FTY720通过对1-磷酸鞘氨醇受体的激动活性,抑制淋巴细胞从次级淋巴组织和胸腺中逸出。
Pharmacol Ther. 2005 Dec;108(3):308-19. doi: 10.1016/j.pharmthera.2005.05.002. Epub 2005 Jun 13.
7
FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function.FTY720:鞘氨醇-1-磷酸受体-1在淋巴细胞流出及内皮屏障功能调控中的作用
Am J Transplant. 2004 Jul;4(7):1019-25. doi: 10.1111/j.1600-6143.2004.00476.x.
8
Pulmonary endothelial cell barrier enhancement by FTY720 does not require the S1P1 receptor.FTY720增强肺内皮细胞屏障功能并不依赖于S1P1受体。
Cell Signal. 2007 Aug;19(8):1754-64. doi: 10.1016/j.cellsig.2007.03.011. Epub 2007 Apr 6.
9
[A new therapeutic approach for autoimmune diseases by the sphingosine 1-phosphate receptor modulator, fingolimod (FTY720)].鞘氨醇-1-磷酸受体调节剂芬戈莫德(FTY720)治疗自身免疫性疾病的新方法
Nihon Rinsho Meneki Gakkai Kaishi. 2009 Apr;32(2):92-101. doi: 10.2177/jsci.32.92.
10
FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation.FTY720(芬戈莫德)在多发性硬化症动物模型中的疗效需要星形胶质细胞鞘氨醇 1-磷酸受体 1(S1P1)的调节。
Proc Natl Acad Sci U S A. 2011 Jan 11;108(2):751-6. doi: 10.1073/pnas.1014154108. Epub 2010 Dec 21.

引用本文的文献

1
Hybrid Lymphatic Drug Delivery Vehicles as a New Avenue for Targeted Therapy: Lymphatic Trafficking, Applications, Challenges, and Future Horizons.混合淋巴递药系统作为靶向治疗的新途径:淋巴转运、应用、挑战与未来展望。
J Membr Biol. 2023 Jun;256(3):199-222. doi: 10.1007/s00232-023-00280-2. Epub 2023 Feb 8.
2
New extracellular factors in glioblastoma multiforme development: neurotensin, growth differentiation factor-15, sphingosine-1-phosphate and cytomegalovirus infection.多形性胶质母细胞瘤发展中的新细胞外因子:神经降压素、生长分化因子-15、鞘氨醇-1-磷酸与巨细胞病毒感染。
Oncotarget. 2018 Jan 9;9(6):7219-7270. doi: 10.18632/oncotarget.24102. eCollection 2018 Jan 23.
3
FTY720 Attenuates Angiotensin II-Induced Podocyte Damage via Inhibiting Inflammatory Cytokines.
FTY720通过抑制炎性细胞因子减轻血管紧张素II诱导的足细胞损伤。
Mediators Inflamm. 2017;2017:3701385. doi: 10.1155/2017/3701385. Epub 2017 Feb 7.
4
Identification of a novel mechanism of action of fingolimod (FTY720) on human effector T cell function through TCF-1 upregulation.通过上调TCF-1鉴定芬戈莫德(FTY720)对人效应T细胞功能的新型作用机制。
J Neuroinflammation. 2015 Dec 30;12:245. doi: 10.1186/s12974-015-0460-z.
5
From sewer to saviour - targeting the lymphatic system to promote drug exposure and activity.从下水道到救星——靶向淋巴系统以提高药物暴露和活性。
Nat Rev Drug Discov. 2015 Nov;14(11):781-803. doi: 10.1038/nrd4608. Epub 2015 Oct 16.
6
Engineering in vivo gradients of sphingosine-1-phosphate receptor ligands for localized microvascular remodeling and inflammatory cell positioning.用于局部微血管重塑和炎症细胞定位的鞘氨醇-1-磷酸受体配体的体内梯度工程。
Acta Biomater. 2014 Nov;10(11):4704-4714. doi: 10.1016/j.actbio.2014.08.007. Epub 2014 Aug 13.
7
Fingolimod attenuates splenocyte-induced demyelination in cerebellar slice cultures.芬戈莫德可减轻小脑切片培养物中脾细胞诱导的脱髓鞘现象。
PLoS One. 2014 Jun 9;9(6):e99444. doi: 10.1371/journal.pone.0099444. eCollection 2014.
8
Protective effect of FTY720 on several markers of liver injury induced by concanavalin a in mice.FTY720对刀豆蛋白A诱导的小鼠肝损伤若干标志物的保护作用。
Curr Ther Res Clin Exp. 2012 Sep;73(4-5):140-9. doi: 10.1016/j.curtheres.2012.07.001.
9
Investigating the molecular mechanisms through which FTY720-P causes persistent S1P1 receptor internalization.研究FTY720-P导致S1P1受体持续内化的分子机制。
Br J Pharmacol. 2014 Nov;171(21):4797-807. doi: 10.1111/bph.12620.
10
Sphingosine-1-phosphate in chronic intestinal inflammation and cancer.慢性肠道炎症和癌症中的1-磷酸鞘氨醇
Adv Biol Regul. 2014 Jan;54:112-20. doi: 10.1016/j.jbior.2013.10.001. Epub 2013 Oct 16.